U.S. FDA approves talazoparib with enzalutamide for metastatic HRR-mutated prostate cancer
PFE•The U.S. FDA approved talazoparib with enzalutamide for metastatic HRR-mutated prostate cancer.
1. FDA approval
The U.S. FDA approved talazoparib with enzalutamide for metastatic HRR-mutated prostate cancer.
